"That's because in the past our Japanese parent companies traditionally licensed our products to larger companies to market," explains Pieroni. "Sankyo discovered the statins, a lipid-lowering class of drugs which are now the mainstay of today's cholesterol reduction. Sankyo discovered the first statin, mevastatin, and co-discovered lovastatin with Merck, the first statin to be marketed. We also developed pravastatin sodium, which we licensed to Bristol-Myers Squibb. Daiichi discovered levofloxacin, an antibiotic for bacterial infections, which is marketed in the U.S. by Johnson & Johnson. Because these innovative and blockbuster products were out-licensed to large U.S. companies, Daiichi Sankyo is not exactly a household name in the U.S."
Sankyo and Daiichi merged in the U.S. in 2006 to form Daiichi Sankyo, Inc. and established its headquarters in Parsippany, N.J. From 2002 to 2007, the company's headquarters staff in Parsippany nearly doubled, its Edison, N.J.- based global Clinical Development staff more than doubled, and its national sales force grew by more than two and one-half times.
Daiichi Sankyo currently employs about 600 people in the state, including 300 at its Parsippany headquarters and 220 at the company's Clinical Development offices in Edison. Nationally, the company employs more than 2,000 people, with about 30 percent of its work force based in New Jersey.
The company develops and markets drugs in five therapeutic areas: cardiovascular, metabolic disease, oncology, immunology and anti-infectives.
The company expects that three anticipated product launches will
continue to fuel its double-digit growth within the next two years. On
September 26, 2007, the Food and Drug Administration approved the company's
new anti- hypertensive drug, AZORTM (amlodipine and olmesartan medoxomil),
a fixed-dose co
'/>"/>
| SOURCE Daiichi Sankyo, Inc. Copyright©2007 PR Newswire. All rights reserved |